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Clinical utility of 18F-FDG PET/CT 
in the follow-up of a large cohort 
of patients with high-risk 
differentiated thyroid carcinoma
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ABSTRACT
Objective: To evaluate the clinical utility of 18F-FDG PET/CT in patients with high-risk DTC. Subjects 
and methods: Single-center retrospective study with 74 patients with high-risk differentiated thyroid 
cancer (DTC), classified in 4 groups. Group 1: patients with positive sTg or TgAb, subdivided in Group 
1A: negative RxWBS and no foci of metastases identified at conventional image (n = 9); Group 1B: 
RxWBS not compatible with suspicious foci at conventional image or not proportional to sTg level (n 
= 13); Group 2: patients with histological findings of aggressive DTC variants (n = 21) and Group 3: 
patients with positive RxWBS (n = 31). Results: 18F-FDG PET/CT identified undifferentiated lesions and 
helped restage the disease in groups 1B and 2. The scan helped guide clinical judgment in 9/13 (69%) 
patients of group 1B, 10/21 (48%) patients of group 2 and 2/31 (6%) patients of group 3. There was no 
clinical benefit associated with group 1A. 18F-FDG PET/CT was associated with progressive disease. 
Conclusion: 18F-FDG PET/CT is a useful tool in the follow-up of patients with high-risk DTC, mainly in 
the group of RxWBS not compatible with suspicious foci at conventional image or not proportional 
to sTg level and in those with aggressive DTC variants. Additionally, this study showed that 18F-FDG 
PET/CT was associated with progression and helped display undifferentiated lesions guiding clinical 
assessments regarding surgeries or expectant treatments. Arch Endocrinol Metab. 2017;61(5):416-25.
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INTRODUCTION
T he routine follow-up of patients with differentiated thyroid cancer (DTC) after surgery 
and radioiodine (RAI) remnant ablation comprises the 
measurement of serum thyroglobulin (sTg), cervical 
ultrasound (US), whole-body scan with 131I (WBS) or 
conventional imaging techniques, such as computed 
tomography (CT) or magnetic resonance imaging 
(MRI).
However, serum Tg levels may not be a reliable 
tool in some patients, mainly due to the presence 
of anti-thyroglobulin antibodies (TgAb) (1) or to 
undifferentiated tumors that do not secrete Tg. 
Similarly, WBS may fail to localize residual thyroid 
tissue in less differentiated tumors due to its impaired 
ability to concentrate RAI (2). 
In recent years, combined 18F-fluorodeoxyglucose 
positron emission tomography/computed tomography 
(18F-FDG PET/CT) has emerged as a valuable tool 
in the follow-up of thyroid cancers. By correlating 
the metabolic information of 18F-FDG PET with the 
morphologic resolution of CT and due to the enhanced 
glucose metabolism in thyroid cancers, particularly in 
less differentiated tumors, this imaging technique 
has been employed beyond the classical indication of 
DTC patients with positive sTg and negative WBS. 
Furthermore, current applications extend to disease 
extension, including the detection of undifferentiated 
metastases (3), guidance of therapy assessments and 
prediction of prognosis (4-6). Some studies have shown 
that 18F-FDG PET and 18F-FDG PET/CT can induce 
changes in clinical management plans in 10-78% of 
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patients with DTC (7-12), thereby improving clinical 
judgment. In the Brazilian population, there has been 
only one study using 18F-FDG PET/CT in thyroid 
cancer patients with negative WBS and positive sTg in 
a small patient sample (13). 
The potential to induce changes in the clinical 
management and the lack of other studies in our 
country motivated this work. Therefore, the aim was to 
evaluate the clinical utility of the 18F-FDG PET/CT in 
a large cohort of patients with DTC in various groups. 
SUBJECTS AND METHODS
A total of 644 patients with DTC were referred, 
evaluated, treated and followed by a single team of 
physicians at the associated Thyroid Disease Centers 
in the Division of Endocrinology, Department of 
Medicine, Escola Paulista de Medicina, Universidade 
Federal de São Paulo and the Instituto Israelita de Ensino 
e Pesquisa Albert Einstein (in São Paulo, Brazil). In this 
population, 80 patients were submitted to 18F-FDG 
PET/CT scans from February 2008 to June 2013. Six 
patients were lost to follow-up; the medical records of 
the remaining 74 patients (who performed 95 total 
18F-FDG PET/CT scans) were analyzed retrospectively. 
This study was approved by the Institutional Ethics 
Committee.
644 patients with DTC
FDG-PET/CT (n = 80)
FDG-PET/CT (n = 74)
Group 1
Positive sTg or TgAb (n = 22)
I
II Clinical relevance
n = 0/9
* CI: conventional images.
Clinical relevance
n = 9/13 (69%)
Clinical relevance
n = 10/21 (48%)
Clinical relevance
n = 2/31 (6%)
1A. patients with positive sTg or TgAb,
negative RxWBS and no foci of metastases
identied at CI (n = 9)
1B. patients with positive
sTg or TgAb, and RxWBS not compatible with
suspicions foci at CI and/or not proportional to 
sTg level (n = 13)
Group 2
Aggressive variants (n = 21)
Group 3
Positive RxWBS (n = 31)
Insufcient data (n = 6)
Figure 1. Schematic representation of the groups (I) and the clinical relevance (II).
According to the medical indications of 18F-FDG 
PET/CT, the 74 patients were classified in 4 groups 
(Figure 1, part I); clinical and epidemiological 
information is shown in Table 1:
• Group 1. Patients with positive sTg or TgAb 
were subdivided in Group 1A (n = 9): nega-
tive post-therapeutic -131 whole body scan 
(RxWBS) and no foci of metastases identified 
at conventional image, and Group 1B (n = 13): 
RxWBS not compatible with suspicious foci 
at conventional image or not proportional to 
sTg level. 
• Group 2. Patients with histological findings of 
aggressive DTC variants (n = 21): oncocytic (n 
= 3), poorly differentiated areas (n = 2), tall-cell 
(n = 4), diffuse sclerosing (n = 4), insular (n 
= 5) and solid variant (n = 3) with incomplete 
biochemical or structural disease. 
• Group 3. Patients with positive RxWBS (n = 
31): in this group, 18F-FDG PET/CT was per-
formed to detect additional foci of undifferen-
tiated metastases.
In the beginning of the study, 59 of 95 
18F-FDG PET/CT scans were performed after TSH 
stimulation (Tg/TSH): hypothyroidism, TSH > 
30 mcUI/mL or after recombinant human TSH, 
rhTSH, Genzyme Transgenics Corp., Cambridge, 
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Massachusetts. Over the course of follow-up, the 
literature demonstrated that despite studies showing 
that the number of positive scans and standard uptake 
value (SUV) increase under rhTSH stimulation, 
there was no conclusive evidence that those findings 
improve clinical management (12,14). Consequently, 
the remaining 36 scans were performed using LT4 
(Tg/LT4). 18F-FDG PET/CT imaging and analysis 
were performed in accordance with the protocol 
described by Yamaga and cols. (13). 
For the predictive value analysis, the following 
criteria defined by Hooft and cols. (15) were used: 
1) histology/cytology; 2) US-FNAC for cervical 
lesions; 3) focal 131I-uptake; 4) pathognomonic bone 
scan or MRI for bone metastases; 5) CT/MRI for 
brain metastases; and 6) progression of radiological 
documented lesions suspect for malignancy. The results 
were considered positive in the presence of 18F-FDG 
uptake in suspected lesions (visualized on conventional 
image) or in those patients with biochemical disease. 
Table 1. Clinical and epidemiological data
Clinical variables Results
Sex Female n = 57/Male n = 17
Total thyroidectomy Yes n = 74
Lymph node resection Yes: 57/No: 17
Age at diagnosis (years) Median 40.9 (12-82)
Age at PET/CT (years) Median 47.6 (16-85)
Follow up after PET/CT 
(months)*
Median 32.4 (7-72)
Group 1A (n = 9)
sTg (ng/mL)
TgAb+
Median of accumulated 
activity (mCi)
n = 6: 0.2-4.9 (Tg/LT4)/3.9-7.4 (Tg/TSH)
n = 2
350 (200-750)
Group 1B (n = 13)
sTg (ng/mL)
TgAb+
Median of accumulated 
activity (mCi)
n = 7: 0,6-91 (Tg/LT4)/2.4-292 (Tg/TSH)
n = 5
375 (230-700)
Group 2 (n = 21)
sTg (ng/mL)
TgAb+
Median of accumulated 
activity (mCi)
n = 20: 0.1-898 (Tg/LT4)/0.1-1000 (Tg/TSH)
n = 1 
250 (100-1000)
Group 3 (n = 31)
sTg (ng/mL)
TgAb+
Median of accumulated 
activity (mCi)
n = 30: 0.1-47 (Tg/LT4)/0.2-168 (Tg/TSH)
1
450 mCi (150-800)
* From the first FDG-PET/CT; sTg: serum thyroglobulin; Tg/LT4: unstimulated Tg; Tg/TSH: 
stimulated Tg.
The results were considered negative if there was no 
18F-FDG uptake. All patients underwent cervical US 
as the routine serial assessment, and suspicious cervical 
lesions were submitted to US-guided fine-needle 
aspiration cytology (US-FNAC) (16). Conventional 
imaging was performed during the follow-up if necessary 
(high levels of sTg measurements, WBS uptake, lung, 
retropharyngeal or bone suspicious metastases). 
Serum Tg levels were measured by a highly sensitive 
chemiluminescence assay (Tg Access immunoassay, 
Beckman Coulter, Brea, CA) with a functional sensitivity 
of 0.1 ng/mL. TSH levels were measured using a third-
generation assay that provided a functional sensitivity 
of 0.05 mUI/mL (17).
According to the combined and serial data of 
conventional imaging, the patient’s clinical status was 
classified as stable or progressive disease. Progressive 
disease was defined as an increase in tumor size during 
the follow-up, and stable disease was defined as stability 
of the lesions. Then, we analyzed the association 
between 18F-FDG uptake and progressive disease. We 
also studied the association between the PET/CT 
results and sTg levels using the cutoff recommended 
by ATA, 10 ng/mL. 
For the continuous variables, the difference between 
positive and negative 18F-FDG PET/CT groups was 
assessed using the Mann-Whitney test. The ROC 
curve was used for the continuous variables to calculate 
the best cut-off point. The chi-square test was used 
to determine the differences in the frequency of the 
categorical variables. A p < 0.05 result was considered 
significant.
RESULTS 
18F-FDG PET/CT results and clinical relevance 
Group 1A: patients with positive sTg or TgAb, 
negative RxWBS and no foci of metastases identified 
at conventional image (n = 9) 
Ten scans were performed in this group. Although 
18F-FDG PET/CT displayed 6 cervical positive lesions 
in only 3 patients, none was confirmed as metastasis 
based on US-FNAC. The sTg levels in this group 
were 0.2-4.9 ng/mL (Tg/LT4) and 3.9-7.4 ng/mL 
(Tg/TSH).
In conclusion, 18F-FDG PET/CT did not provide 
additional information in this group of patients.
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Group 1B: patients with positive sTg or TgAb and 
RxWBS not compatible with suspicious foci at 
conventional image or not proportional to sTg level 
(n = 13)
Twenty 18F-FDG PET/CT scans were performed in this 
group of 13 patients, and nine of 13 presented positive 
18F-FDG PET/CT scans (Table 2, patients 1-9). In 
those patients, the results helped clarify lesions visualized 
in conventional images that were RAI negative; in three 
of them, a second 18F-FDG PET/CT demonstrated 
the efficacy of the surgery indicated after the first scan 
results (Table 2, patients 1-3); in other three patients, 
the second 18F-FDG PET/CT was useful to show 
progression of the metastases (Table 2, patients 4, 
6-7). The 18F-FDG PET/CT displayed, in all, cervical, 
mediastinal or retropharyngeal uptake in 4 patients who 
had confirmed metastatic lesions based on histological 
results (Table 2, patients 1-4). One patient (Table 2, 
patient 4) and the remaining 5 (Table 2, patient 5-9) 
presented diffuse pulmonary 18F-FDG uptake. 
In group 1B, we considered that the 18F-FDG 
PET/CT results helped localize metastases in 9/13 (69%). 
Table 2. Clinical and imaging characteristics of group 1B
No RxWBS 
uptake
PET Tg/LT4 Tg/TSH CT/RM
findings
PET-CT
findings
Management Clinical
Relevance
1 Negative A 21 26 Thyroid bed 
Mediastinum   
Retropharingeaum
Thyroid bed 
Mediastinum   
Retropharingeaum
Surgery Yes
B 8.7 - Thyroid bed
Retropharingeaum
Thyroid bed
Retropharingeaum
Expectant
2 Negative A 1.9 97 - Mediastinum Surgery Yes
B 3.8 - - Cervical Expectant
3 Negative A 0.5* - - Cervical Surgery Yes
B 0.1* - Retropharingeaum Retropharingeaum Expectant
4 Cervical A 1.5 48 Thyroid bed
Lung
Thyroid bed Expectant Yes
B 14 173 Thyroid bed
Mediastinum
Lung
Thyroid bed
Mediastinum
Lung
Surgery
5 Cervical A 0.5* - Paratracheal
Lung
Esophagus
Paratracheal
Lung
Esophagus
Expectant Yes
6 Negative A 0.4* - Lung Lung Expectant Yes
B 0.1* - Lung Progression of the 
lesions**
Expectant
7 Negative A 13 292 Lung Lung Expectant Yes
B 91 - Lung Progression of the 
lesions**
Expectant
8 Negative A 5000* 1000* Hilar mass lung Lung atelectasis Expectant Yes
9 Cervical A 0.8* Mediastinum
Paratracheal
Lunge
Mediastinum
Paratracheal
Lunge
Expectant Yes
10 Cervical A 0.6 4.8 Mediastinum
Lung
Mediastinum
Lung
Expectant No
11 Negative A 0.8 2.4 Mediastinum None Expectant No
12 Negative A 3.7 5.1 Lung None Expectant No
13 Cervical A 18 - Lung Lung Expectant No
PET A, B: 1st, 2nd scans, respectively; RxWBS: Post-Therapeutic -131 Whole Body Scan; Tg/LT4: unstimulated Tg (ng/mL);
Tg/TSH: stimulated Tg (ng/mL). * TgAb positive; ** In relation to 1st PET/CT.
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Group 2: patients with aggressive variants at the 
histological findings with incomplete biochemical or 
structural disease (n = 21) 
Twenty-seven scans were performed in this group of 
21 patients. In 10 of 21 patients, 18F-FDG PET/CT 
provided relevant information.
Oncocytic variant (n = 2): The scan was indicated 
for an undetectable sTg and positive RxWBS cervical 
metastasis uptake, and there was 18F-FDG uptake in 
the cervical subcutaneous tissue. The other patient 
presented with RAI negative but suspicious pulmonary 
lesions on conventional images, and the 18F-FDG 
PET/CT scan showed lung uptake. Both lesions were 
confirmed as metastases based on histological analysis 
(Table 3, patients 1-2), indicating that 18F-FDG 
PET/CT provided relevant information.
Poorly differentiated areas on histology (n = 1): the 
patient presented a positive RxWBS lumbar vertebrae 
metastasis with accelerated elevation of sTg, and the 
positive 18F-FDG uptake suggested possible tumor 
undifferentiation. This patient also presented with 
cerebral metastasis and had been treated with cerebral 
and vertebrae radiotherapy (Table 3, patient 4). 
Table 3. Clinical and imaging characteristics of group 2
No Histology RxWBS
uptake
PET Tg/LT4 Tg/TSH CT/RM
findings
PET-CT
findings
Management Clinical 
Relevance
1 Oncocytic Cervical A 0.6 5.4 - Subcutaneous Surgery Yes
2 Oncocytic Cervical A 278 - Lung Lung Surgery Yes
3 Oncocytic Scapula A 0.1 0.6 Scapula Scapula RAI No
4 Poorly differentiated Spine A 14 767 - Vertebra L4 RAI, RT Yes
5 Poorly differentiated Cervical A 0.1 - Retropharingeaum None Expectant No
6 Insular Ø RAI A 511 1000 Lung None RAI 
Yes
Lung B 44 - Lung None RAI
7 Insular Ø RAI A 3.3 18 Lung None RAI Yes
8
Tall cell
Cervical 
Mediastinum 
Focal lung
A 13 95 Lung Lung Expectant
Yes
B 134 Lung Lung Surgery
C 898 - - Brain RT
D 379 - Kidney, L2 Surgery 
9
Insular
Cervical
Focal lung 
A 1* 3*
Mediastinum
Lung
Cervical
Mediastinum
Lung
Surgery
TKI
Yes
B 4* 6* Mediastinum
Lung
Progression of 
the lesions**
Expectant
10
Tall cell
Negative A 89 - Lung Lung Surgery
Yes
B 104 635 Lung Lung Expectant
11 Tall cell Cervical A 17 42 Lung Lung Expectant Yes
12 Solid trabecular Cervical A 44 66 Lung Lung Expectant Yes
13 Solid trabecular Negative A 0.2 0.2 - None Expectant No
14 Solid trabecular Mediastinum A 0.2 - Mediastinum Cervical Expectant No
15 Diffuse sclerosing Lung A 0.1 2.7 - Thyroid bed Expectant No
16 Diffuse sclerosing Negative A 1.9 271 Paratracheal None PEI No
17 Diffuse sclerosing Cervical A 0.2 0.1 - None Expectant No
18 Diffuse sclerosing Negative A 1.9 4.3 - None Expectant No
19 Insular Cervical A 428 - Lung None Expectant No
20 Insular Ø RAI A 65 - Cervical Expectant No
21 Tall cell Cervical A 2.4 - - Cervical Expectant No
PET A, B, C, D: 1st, 2nd, 3rd and 4th scans, respectively; PEI: percutaneous injection of ethanol; RAI: radioiodine; RxWBS: Post-Therapeutic -131 Whole Body Scan; Ø RAI: without radioiodine; 
RT: radiotherapy; Tg/LT4: unstimulated Tg (ng/mL); Tg/TSH: stimulated Tg (ng/mL); TKI: tyrosine-kinase inhibitor. * TgAb positive; ** In relation to 1st PET/CT.
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Other aggressive variants (n = 7): 18F-FDG 
PET/CT provided relevant information in 7 patients. 
Two patients without previous RAI treatment 
underwent paired 18F-FDG PET/CT and DxWBS 
scans. A 18F-FDG negative scan combined with positive 
RAI uptake endorsed the first RAI treatment indication 
(Table 3, patients 6-7). The other 5 patients had 
18F-FDG uptake in pulmonary nodules, suggesting 
undifferentiated metastases (Table 3, patients 8-12). 
Three patients underwent resection of the 18F-FDG 
positive metastases (Table 3, patients 8-10), but despite 
treatment, the disease progressed in all patients, and 
one patient presented with renal metastasis confirmed 
on histopathology, cerebral metastasis refractory to 
radiotherapy and death (Table 3, patient 8, Figure 2). In 
this group, the 18F-FDG PET/CT results contributed 
to the clinical management in 10/21 patients (48%).
Group 3: patients with positive RxWBS (n = 31)
This group included 31 patients with positive WBS 
who underwent 39 scans. There was no additional 
18F-FDG uptake suggestive of metastases in respect to 
RxWBS or conventional images. However, 2 patients 
with previous RxWBS positive pulmonary disease 
and increasing sTg/TgAb levels showed pulmonary 
18F-FDG uptake, suggesting tumor undifferentiation. 
In this group of 31 patients, the 18F-FDG PET/CT 
results delineated prognosis in 2 patients (6%). 
The clinical relevance of each group is summarized 
in Figure 1, part II. 
18F-FDG PET/CT result as predictor of progressive 
disease
From the 95 18F-FDG PET/CT scans, we found 
61 positive, 28 negative and 6 indeterminate scans. 
Figure 2. 18F-FDG PET/CT images show increased metabolic activity in 62-y-woman: A. Expansive lesion on frontal lobe of the brain; B. Lytic lesion on 
L2 vertebral body; C. Right lower renal mass. (Table 3, patient 8).
A
B
C
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All eighteen patients who presented with progressive 
disease showed 18F-FDG uptake (100%) compared to 
twenty-nine of fifty-six patients who were stable (52%). 
The 18F-FDG uptake was associated with progressive 
disease (p = 0.0004).
18F-FDG PET/CT results and sTg measurements
The median serum Tg/LT4 was 9.4 ng/mL (0.1-898) 
in the positive PET/CT patients, compared to 0.8 
ng/mL (0.1-44) in the PET/CT negative group 
(p = 0.001). In analyzing the Tg/TSH level, the median 
level in the positive PET/CT patients was 26 ng/mL 
(0.9-1,000), in contrast to 5.1 ng/mL (0.1-271) in the 
PET/CT negative group (p = 0.003) (Table 4A). In 
analyzing each group separately, there was a significant 
difference between the positive and negative PET/CT 
results in group 1 (for both Tg/LT4 and Tg/TSH) and 
group 2 (only for Tg/LT4). If we used the sTg level 
of 10 ng/mL, there were abnormal PET/CT results in 
52% of all patients with Tg/LT4 levels ≤ 10 ng/mL and 
in 90% of patients with Tg/LT4 levels of > 10 ng/mL 
(p < 0.001) (Table 4B). For Tg/TSH, the outcome was 
38% in Tg/TSH levels of ≤ 10 ng/mL versus 74% if Tg/
TSH was > 10 ng/mL (p < 0.009). For each group, 
separately, there was a significant difference in only group 
1 (for both Tg/LT4 and Tg/TSH) and group 2 (only 
for Tg/LT4). 
DISCUSSION 
High metabolic activity revealed by 18F-FDG avidity 
represents advanced tumor and undifferentiation. In 
these cases, poorly differentiated follicular cells might 
lose the ability to concentrate RAI, synthesize sTg, 
and progressively enhance glucose metabolism due 
to high cell activity and metabolic demand. In this 
way, 18F-FDG PET/CT has become a powerful tool 
to improve staging and tumor aggressiveness and 
investigate undifferentiated lesions that do not take 
up radioiodine, denoting important diagnostic and 
prognostic implications (18-20).  
Table 4 – A. The median of thyroglobulin level from 18F-FDG PET/CT positive (FDG +) and negative (FDG -) patients. B. 18F-FDG PET/CT positive result 
according to the cutoff of sTg = 10 ng/mL.
A
FDG + FDG - p
All patients Tg/LT4 (ng/mL) 9.4 (0.1-898) 0.8 (0.1–44) < 0.01
Tg/TSH (ng/mL) 26 (0.9-1000) 5.1 (0.1–271) < 0.01
Group 1 Tg/LT4 (ng/mL) 6.9 (0.5-91) 1.4 (0.1-4.9) < 0.05
Tg/TSH (ng/mL) 72.5 (3.9-292) 5.1 (2.4-7.4) < 0.05
Group 2 Tg/LT4 (ng/mL) 59.1 (0.2-898) 0.2 (0.1-44) < 0.05
Tg/TSH (ng/mL) 95 (0.4-1000) 0.6 (0.1-271) > 0.05
Group 3 Tg/LT4 (ng/mL)  2.2 (0.1-47) 1.0 (0.1-7.9) > 0.05 
Tg/TSH (ng/mL) 13.9 (1.1-168) 8.0 (0.7-38) > 0.05 
Tg/LT4: unstimulated Tg; Tg/TSH: stimulated Tg.
B
18F-FDG PET/CT positive result
Tg ≤ 10 ng/mL Tg > 10 ng/mL p
All patients Tg/LT4 27/52 (52%) Tg/LT4 21/22 (95%) < 0.01
Tg/TSH 10/26 (38%) Tg/TSH 20/27 (74%) < 0.01
Group 1 Tg/LT4 6/13 (46%) Tg/LT4 5/5 (100%) < 0.05
Tg/TSH 1/8 (13%) Tg/TSH 5/5 (100%) < 0.01
Group 2 Tg/LT4 5/11 (45%) Tg/LT4 13/14 (93%) < 0.01
Tg/TSH 4/7 (57%) Tg/TSH 7/9 (78%) > 0.05
Group 3 Tg/LT4 17/29 (59%) Tg/LT4 3/3 (100%) > 0.05
Tg/TSH 5/11 (45%) Tg/TSH 8/13 (62%) > 0.05
Tg/LT4: unstimulated Tg; Tg/TSH: stimulated Tg.
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The classical indication to perform 18F-FDG 
PET/CT in thyroid cancer patients is positive sTg 
measurements with negative WBS uptake (6). In the 
literature, 18F-FDG PET/CT provides additional 
information not revealed by traditional images in 21-
71% of patients, mostly in negative WBS (7,8), and in 
13-50% of patients with positive TgAb (21,22). 
In our study, we analyzed the classical indication 
of 18F-FDG PET/CT in 22 patients with positive sTg 
or TgAb, negative RxWBS and no foci of metastases 
identified at conventional image (Group 1A, n = 9) 
and those with positive sTg or TgAb and RxWBS not 
compatible with suspicious foci at conventional image 
or not proportional to sTg level (Group 1B, n = 13). In 
group 1A, 18F-FDG PET/CT did not detect additional 
metastases. The low sTg levels (0.2-4.9 ng/mL), 
even under stimulation (3.9-7.4 ng/mL), combined 
with microscopic metastasis might explain the lack of 
18F-FDG-avid lesions, as 18F-FDG is limited in detecting 
minimal disease (under 1.0 cm). However, the 18F-FDG 
PET/CT scan helped unveil undifferentiated cervical, 
lung and mediastinal metastases in 9 patients (69%) in 
group 1B. The positive FDG uptake observed in this 
subgroup was associated with higher levels of sTg (Tg/
LT4: 0.6-91 ng/mL and Tg/TSH: 2.4-292 ng/mL) 
and higher dimensions of metastasis. 
In the subgroup 1B, surgery was possible in 4 of 9 
patients with positive 18F-FDG PET/CT scan results. As 
described by Hall and Kloos (3), the ideal of 18F-FDG, 
to identify resectable lesions to pursue a cure, should 
be attempted as undifferentiated lesions are less likely 
to respond to RAI, and additional surgery can lead to a 
higher rate of full remission during follow-up (23). The 
other 6 patients presented diffuse pulmonary 18F-FDG 
uptake, and there was no role for surgery.  
The other aspect to consider is the behavior of 
aggressive histological variants. Those variants have 
unfavorable prognosis as they feature low iodine 
avidity and aggressive clinical behavior with more local 
and distance recurrences, less disease-free intervals 
and shorter survivals, requiring close follow-up and 
continued surveillance to pursue occult metastases. 
Publications regarding 18F-FDG PET/CT and 
aggressive variants describe these subtypes as more 
18F-FDG-avid than RAI tumors. Concerning oncocytic 
cell tumors, 80% of patients have no iodine-avid tumor 
(24), and therefore, 18F-FDG PET/CT is a valuable tool 
for screening occult recurrence, evaluating prognosis, 
and providing additional images not presented by WBS 
or conventional image (25,26). In regard to the other 
aggressive subtypes, few studies consider 18F-FDG 
PET/CT as a useful guide in the management of 
insular (27), sclerosing diffuse (28) and tall cell (29) 
variants. Treglia and cols. (30) concluded that the 
18F-FDG PET scan usefulness is clear for the oncocytic 
cell, uncertain for poorly differentiated cancers and 
suggestive in the other aggressive forms. The concept 
of tumor undifferentiation was also observed in 
patients in group 2 (n = 21). In our study, the results 
corroborate the findings in the literature. The higher 
FDG uptake presented in this group can be attributed 
to more undifferentiated thyroid tumors with more avid 
uptake for 18F-FDG and high levels of sTg. Pryma and 
cols. (25) suggested that 18F-FDG PET/CT could be 
indicated in oncocytic cell carcinoma in postoperative 
staging and as follow-up in patients with an increase 
in sTg or recurrent disease, whereas Nascimento and 
cols. (29) recommended routine early postoperative 
18F-FDG PET/CT concomitantly with RxWBS in all 
patients with aggressive histological DTC.   
18F-FDG and RAI may function as complementary 
tools in DTC (9,31) to investigate additional 
undifferentiated metastases. However, in our cohort, 
we did not find additional metastases visualized by 
WBS. WBS-positive patients have no classical indication 
for 18F-FDG PET/CT and cost-efficacy must be 
considered in WBS positive group patients.
ATA recommends 18F-FDG PET/CT in high-
risk DTC patients with elevated sTg, generally Tg/
TSH > 10 ng/mL (6). If Tg/TSH is ≤ 10 ng/mL, 
the sensitivity of PET/CT is low, ranging from less 
than 10% to 30% (6). In our data, 38% of all scans 
performed with Tg/TSH of ≤ 10 ng/mL and 13% of 
group 1 were positive, similar to the literature data. In 
contrast, 74% of PET/CT performed with Tg/TSH 
of > 10 ng/mL provided positive results (as was the 
case for 100% of group 1). Regarding unstimulated 
Tg analysis, Tg/LT4 > 10 ng/mL was associated with 
higher lesion detection in overall patients and groups 
1 and 2 when compared to Tg/LT4 ≤ 10 ng/mL. As 
a matter of fact, more important than the influence of 
rhTSH or thyroid hormone withdrawal in 18F-FDG 
PET/CT is the presence of high levels of Tg (Tg/
TSH or Tg/LT4 > 10 ng/mL). Over the last years, 
it has been demonstrated that both strategies, with or 
without TSH stimulation, do not considerably lead to 
management changes (12,32).  
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Additional factors than sTg that influence 18F-FDG 
PET/CT sensitivity are tumor de-differentiation and 
larger tumor burden (6), as we have seen in our results. 
Additionally, the scanning is limited in detecting minimal 
disease (generally less than 1 cm) and well-differentiated 
metastases, resulting in false negative outcomes. It is 
well known that inflammatory lesions can take up FDG, 
and there may be false positive results. All these features 
should be considered with care to avoid misjudgments. 
The frequency of false positive lesions in the literature 
varies among studies from 0 to 39% (6), and this high 
number justifies the PET/CT results through the 
combined data of clinical, laboratorial, conventional 
image and cytological/histological information to 
guide ongoing clinical assessments. 
The present work has some limitations. First, this 
was a retrospective study, and direct comparison of 
the detection rate of metastases between 18F-FDG 
PET/CT and other diagnostic methods was not the 
design of this study. Additionally, we had no cytological 
or pathological confirmation of all lesions with 18F-FDG 
uptake. Based on the serial evaluation of thyroid cancer 
patients with laboratorial and image exams to assess 
tumor growth, invasive procedure to confirm the 
metastases is seldom necessary.
In conclusion, 18F-FDG PET/CT results changed 
the management in 28% (21/74) of patients, mostly 
in 1B group, patients with RxWBS not compatible 
with suspicious foci at conventional image or 
not proportional to sTg level (69%, 9/13) and in 
group 2, patients with aggressive histological variant 
patients (48%, 10/21), confirming the literature 
indications that 18F-FDG PET/CT is more useful in 
these two groups of patients. For group 1A patients, 
with positive sTg or TgAb, negative RxWBS and 
no foci of metastases identified at the conventional 
image, 18F-FDG PET/CT was not useful, probably 
due to low levels of sTg and low tumor burden. 
Additionally, this study showed that 18F-FDG uptake 
was associated with progressive disease and helped 
display undifferentiated lesions guiding clinical 
assessments with respect to surgeries or expectant 
treatments. 
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